Related Experiment Video
Updated: May 28, 2025
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
Published on: July 23, 2016
Development and evaluation of siRNA-mediated gene silencing strategies for ADO2 therapy utilizing iPSCs model and
Jiajun Xu1,2, Gengshuo Chen1,2, Chune Mo1,2
1Laboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, China.
Background:
Autosomal dominant osteodystrophy type II (ADO2) is an inherited disease characterized by an abnormal increase in bone mineral density, and CLCN7 (R286W) is its most common causative mutation. The aim of this study was to explore the new idea of siRNA technology applied to the in vitro treatment of ADO2.
Methods:
Urinary-derived cells from ADO2 patients were collected to establish induced pluripotent stem cells (iPSCs) model. The siRNA targeting CLCN7 (R286W) mutant mRNA was designed. the cytotoxicity of the delivery vector DMPC-SPIONs was comprehensively evaluated by CCK-8 assay, flow cytometry and scratch assay. Finally, qPCR was utilized to verify the post-transcriptional silencing effect of siRNAs.
Results:
We found that DMPC-SPIONs had low cytotoxicity and were able to effectively deliver siRNAs into ADO2-iPSCs. qPCR confirmed that siRNA-DMPC-SPIONs were able to significantly reduce the expression level of mutant CLCN7 (66%), while there was no significant effect on the expression of wild-type CLCN7.
Conclusions:
This study developed a gene silencing strategy based on siRNAs and DMPC-SPIONs, which provides a potential new approach for the treatment of ADO2 and demonstrates the potential application of siRNA technology in the treatment of autosomal dominant genetic diseases.
Innovative Statements:
In this study, we used the established ADO2-iPSCs using patient's urine-derived cells to explore the safety and efficacy of siRNA technology based on the principle of RNA interference for ADO2 treatment for the first time. In addition, we chose DMPC-SPIONs as the delivery vehicle for siRNA, which cleverly exploits the advantages of nanoparticles such as superparamagnetism, low cytotoxicity, and good bio-histocompatibility.
Insights
This study demonstrates siRNA technology effectively reduces mutant CLCN7 expression in Autosomal dominant osteodystrophy type II (ADO2) patient cells. DMPC-SPIONs show low cytotoxicity, offering a promising new therapeutic strategy for ADO2.
Area of Science:
- Genetics and Molecular Biology
- Stem Cell Biology
- Nanomedicine
Background:
- Autosomal dominant osteodystrophy type II (ADO2) is a genetic disorder causing increased bone density.
- The CLCN7 (R286W) mutation is the most frequent cause of ADO2.
- Current treatment options for ADO2 are limited.
Purpose of the Study:
- To investigate the potential of siRNA technology for treating ADO2 in vitro.
- To evaluate the efficacy and safety of siRNA delivered by DMPC-SPIONs in ADO2 patient-derived cells.
Main Methods:
- Established induced pluripotent stem cells (iPSCs) from ADO2 patient urine-derived cells.
- Designed siRNA targeting the mutant CLCN7 mRNA.
- Assessed DMPC-SPIONs' cytotoxicity and siRNA delivery efficiency.
- Utilized qPCR to confirm gene silencing.
Main Results:
- DMPC-SPIONs exhibited low cytotoxicity and effectively delivered siRNA into ADO2-iPSCs.
- siRNA-DMPC-SPIONs significantly reduced mutant CLCN7 mRNA expression by 66%.
- No significant impact was observed on wild-type CLCN7 expression.
Conclusions:
- Developed a novel gene silencing strategy for ADO2 using siRNA and DMPC-SPIONs.
- Demonstrated the potential of siRNA technology for treating ADO2 and other autosomal dominant genetic diseases.
- Highlighted the advantages of DMPC-SPIONs as a biocompatible nanoparticle delivery system.
More Related Videos
Related Concept Videos
02:15Experimental RNAi
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
01:22iPS Cell Differentiation